Headquartered in Austin, TX Fiscal year ends December NASDAQ: STTK shattucklabs.com
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on the development of potentially first-in-class monoclonal and bispecific DR3 (Death Receptor 3) blocking antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate, SL-325, is a DR3 blocking antibody targeting Crohn's disease, ulcerative colitis, and other inflammatory conditions by achieving complete blockade of the clinically validated DR3/TL1A pathway. Its second product candidate, SL-846, is a bispecific antibody simultaneously blocking DR3 and IL-23 receptor pathways. The company leverages proprietary protein engineering expertise to develop novel TNF receptor therapeutics. Shattuck generates no revenue and funds operations through equity capital raises. The company trades on NASDAQ under the ticker STTK. Updated
Markets took a brutal hit Thursday as oil prices, surging interest rates, and Middle East tensions sent every major index deep into the red. See which stocks analysts are upgrading, downgrading, and…
The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't the only notable buy in the past week or so.
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on the development of potentially first-in-class monoclonal and bispecific DR3 (Death Receptor 3) blocking antibodies for the treatment of inflammatory and immune-mediated diseases.
The Wall Street consensus 12-month price target for STTK is $15.22.
